Synapse - Works

Results (22057)

SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Meeting Abstract

Shitara, K.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shah, M. A.; van Cutsem, E.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)

Meeting Abstract

Hong, D. S.; Bang, Y. J.; Barlesi, F.; Durm, G.; Falchook, G. S.; Govindan, R.; Dy, G. K.; Park, K.; Strickler, J. H.; Burns, T. F.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update

Meeting Abstract

Kang, Y. K.; Jones, R. L.; von Mehren, M.; Serrano, C.; George, S.; Heinrich, M. C.; Schoffski, P.; Mir, O.; Cassier, P. A.; Eskens, F.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Meeting Abstract

Xu, R. H.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shitara, K.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study

Meeting Abstract

Yoshino, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Henrik Jensen, L; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

Meeting Abstract

Qin, S.; Tabernero, J.; van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D.; Bang, Y. J.
Annals of Oncology (2020)

Fulltext@MSK | Save

HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

Meeting Abstract

Masuda, N.; Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; O'Shaughnessy, J.; Xie, D.; Walker, L.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC

Meeting Abstract

Saji, S.; Llombart Cussac, A.; Andre, F.; Robson, M. E.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Ahn, J. S.; Nanda, R.; Fan, L.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)

Meeting Abstract

Chiu, C. F.; Yeh, Y. M.; Yeh, K. H.; Desai, J.; Price, T. J.; Tebbutt, N.; Tabernero, J.; Velez, L.; Trevino, T. L.; Grothey, A.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline

Guidelines

Gordan, J. D.; Kennedy, E. B.; Abou-Alfa, G. K.; Beg, M. S.; Brower, S. T.; Gade, T. P.; Goff, L.; Gupta, S.; Guy, J.; Harris, W. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save